ABT Jun 2024 150.000 call
| Previous Close | 0.1500 |
| Open | 0.0700 |
| Bid | 0.0000 |
| Ask | 0.1000 |
| Strike | 150.00 |
| Expire Date | 2024-06-21 |
| Day's Range | 0.0700 - 0.1500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 108 |
ZacksAbbott (ABT) Rises Higher Than Market: Key Facts
Abbott (ABT) closed the most recent trading day at $104.29, moving +0.64% from the previous trading session.
Motley FoolAbbVie Should Consider a Dividend Cut -- Here's Why
Since its split from Abbott Laboratories in 2013, AbbVie (NYSE: ABBV) has been the third best-performing stock in terms of total returns on capital (assuming the dividend was reinvested) on the esteemed list of Dividend Kings. AbbVie's top-shelf performance has been due to two main factors. First up, the company successfully expanded Humira's label at a breakneck pace over this period, transforming it into the world's first pharma product to exceed $20 billion a year in sales.
ZacksWall Street Bulls Look Optimistic About Abbott (ABT): Should You Buy?
According to the average brokerage recommendation (ABR), one should invest in Abbott (ABT). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
